TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospectiv...(PM ICD/CRT ...),Health

Date:5/14/2009

PM ICD/CRT infection infection Implant Type implants infections rate implants infections rate De novo 15 0 0.0% 51 0 0.0% Revision 38 0 0.0% 141 1 0.4% Total 53 0 0.0% 192 1 0.4% Other Total infection infection Implant Type implants infections rate implants infections rate De novo 1 0 0.0% 67 0 0.0% Revision 8 0 0.0% 187 1 0.4% Total 9 0 0.0% 254 1 0.4%

Dr. Dan Lerner, TYRX's Chief Medical Officer, noted that "when one looks at the characteristics of the patients enrolled in the AIGIS Retrospective Registry to-date it is noteworthy that there is a high percentage of patients who are, according to published studies, at high risk of CRMD-related infections."

                                                             Greater than
                                                             or equal to 1
                                                              Follow-up
       Risk Factors for developing a CRMD       All            Visit
                    infection                 n = 393          n = 254
                                              n     %         n      %
                                     CHF     218   55.5      152    59.8

             Chronic Renal Insufficiency      93   23.7       56    22.1

                   Chronic Renal Failure      41   10.4       24     9.5

                     Oral anti-coagulant     140   35.6       90    35.4

'/>"/>
SOURCE  TYRX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 
Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens